Menotropins
- Atc Codes:G03GA02
- CAS Codes:9002-68-0
- PHARMGKB ID:9002-68-0
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Menopur; Belgium: Menopur; Bulgaria: Menogon, Menopur; Cyprus: Merional; Czech Republic: Menogon, Menopur, Merional; Denmark: Menopur; Finland: Menopur; France: Menopur; Germany: Menogon, Menopur; Greece: Menopur, Merional; Hungary: Menopur; Ireland: Menopur; Italy: Menogon, Meropur; Luxembourg: Menopur; Netherlands: Menogon, Menopur; Poland: Menogon, Menopur; Portugal: Menopur; Romania: Menogon, Menopur; Slovakia: Menogon, Menopur; Slovenia: Menopur; Spain: Menopur; Sweden: Menopur; UK: Menopur, Merional.
North America
Canada: Menopur, Repronex; USA: Menopur, Repronex.
Latin America
Argentina: HMG, Menopur; Mexico: Merapur.
Drug combinations
Chemistry
Menotropins: An extract of human post-menopausal urine containing both follicle-stimulating hormone and luteinizing hormone. Follicle stimulating hormone. CAS-9002-68-0 (1967).
Pharmacologic Category
Hormones and Synthetic Substitutes; Gonadotropins. Ovulation Stimulator. (ATC-Code: G03GA02).
Mechanism of action
Follicle-stimulating hormone effects and luteinizing hormone effects. In males it stimulates spermatogenesis.
Therapeutic use
In conjunction with hCG to induce ovulation and pregnancy in infertile females experiencing oligoanovulation or anovulation. Stimulation of multiple follicle development in ovulatory patients as part of assisted reproductive technology.
Pregnancy and lactiation implications
Ectopic pregnancy and congenital abnormalities reported. Use caution if administered during lactation (unknown if excreted in breast milk).
Unlabeled use
Stimulation of spermatogenesis in primary or secondary hypogonadotropic hypogonadism.
Contraindications
Hypersensitivity to menotropins or any component of the formulation. Primary ovarian failure (high follicle-stimulating hormone level). Uncontrolled thyroid and adrenal dysfunction. Abnormal bleeding of undetermined origin. Intracranial lesion (i.e. pituitary tumor). Ovarian cyst or enlargement not due to polycystic ovary syndrome. Infertility due to any cause other than anovulation (except candidates for in vitro fertilization). Sex hormone-dependent tumors of the reproductive tract and accessory organs. Pregnancy.
Warnings and precautions
Ovarian enlargement might be accompanied by abdominal distention or abdominal pain. Ovarian hyperstimulation syndrome might occur. Serious pulmonary effects (atelectasis, acute respiratory distress syndrome, and exacerbation of asthma) reported. Thromboembolism reported. Use with caution in hepatic or renal impairment. Products might contain lactose. Potential risk of multiple births.